



# Severe Aplastic Anaemia Working Party Educational Course

Basel, Switzerland  
9-11 October 2025

## WORD OF WELCOME

Dear Colleagues and Friends,

This year, the Severe Aplastic Anaemia Working Party Educational Course will be held in Basel, Switzerland, from 9-11 October 2025. It will be a great pleasure to welcome international physicians and experts with a special interest in aplastic anemia, on behalf of SAAWP EBMT.

The conference will feature comprehensive sessions on acquired aplastic anemia, inherited bone marrow failure and paroxysmal nocturnal hemoglobinuria.

We are aiming to share knowledge, foster collaboration and advance our understanding in the field of aplastic anemia, paving the way for the future studies to be conducted by our Working Party.

And this scientific discussion will also give us the opportunity to honor our mentors who have pioneered the field of aplastic anemia.

We look forward to welcoming you to Basel!

**Antonio Risitano** - *Severe Aplastic Anaemia Working Party Chair*

**Austin Kulasekararaj** - *Severe Aplastic Anaemia Working Party Secretary*

**Jakob Passweg** - *Severe Aplastic Anaemia Working Party Local Organiser*

**Beatrice Drexler** - *Severe Aplastic Anaemia Working Party Local Organiser*

**Kelly Hennessy** - *Severe Aplastic Anaemia Working Party nurse*

## Thursday, 9 October 2025

13:00 – 14:00

### Session I: Pathogenesis of acquired AA

**Chairs:** Edward Gordon-Smith (UK) & Andrea Bacigalupo (IT)

13:00 – 13:20

From a genetic point of view

Marcin Wlodarski (DE)

13:20 – 13:40

From an immunology point of view

Leo Hansmann (DE)

13:40 – 14:00

HLA and AA: Friends or Foe

Shinji Nakao (JP)

14:00 – 15:30

### Session II: 30 years in AA – What have we learned

**Chairs:** Austin Kulasekararaj (UK) & Antonio Risitano (IT)

14:00 – 14:20

Diagnosis

Alicia Rovó (CH)

14:20 – 14:40

Treatment I: Transplantation

Andrea Bacigalupo (IT)

14:40 – 15:00

Treatment II: IST

Jakob Passweg (CH)

15:00 – 15:20

Long-term outcome and late effects

André Tichelli (CH)

15:20 – 15:30

Discussion: What have learned in 30 years

15:30 – 16:00

### Coffee Break

16:00 – 16:45

### Industry Symposium kindly sponsored by Alexion:

#### Scaling New Heights in PNH: Navigating the Path of Dual Complement Inhibition

**Chair:** Austin Kulasekararaj (UK)

16:00 – 16:03

Introduction, welcome, faculty introduction and agenda overview

Talha Munir (UK)

16:03 – 16:18

Terminal Complement Inhibition in PNH: A Foundation for Disease Control

Talha Munir (UK)

16:18 – 16:32

The Next Step in Complement Control: Addressing Extravascular Haemolysis in PNH

Austin Kulasekararaj (UK)

16:32 – 16:40

Panel Discussion/Q&A

All

16:40 – 16:45

Key Takeaways and Closing Remarks

Austin Kulasekararaj (UK)

16:45 – 17:30

### Session III: Inherited BMFs: HCT Versus gene therapy

**Chairs:** Carlo Dufour (IT) & Constantijn Halkes (NL)

16:45 – 17:00

Role of HCT in inherited BMFs

Éliane Gluckman (FR)

17:00 – 17:15

Genetic counselling of families (patients and donor!) with inherited BMFs

Fabian Beier (DE)

17:15 – 17:30

Gene therapy approaches in bone marrow failure syndromes

Senthil Bhoopalan (US)

20:00 – 22:00

### Scientific Business Meeting

## Friday, 10 October 2025

09:00 – 10:00

### Session IV: Complement

**Chairs:** Camilla Frieri (IT) & Jaroslaw Maciejewski (US)

09:00 – 09:20

Complement and disease

Daniel Ricklin (CH)

09:20 – 09:40

Other complement – associated diseases / Benefits of complement inhibitors in other indications

Patricia Hirt-Minkowski (CH)

09:40 – 10:00

Discussion: complement and transplant/more

<b>10:00 – 11:00</b>	<b>Session V: Daily hurdles in AA</b> <b>Chairs:</b> <i>Olaia Naveiras (CH) &amp; Austin Kulasekararaj (UK)</i>	
<b>10:00 – 10:20</b>	Tapering EPAG – How, when and when to re-start again...	Beatrice Drexler (CH)
<b>10:20 – 10:40</b>	Work up and treatment of MAA	Britta Höchsmann (DE)
<b>10:40 – 11:00</b>	How to distinguish “clonal haematopoiesis” from “transformation” in AA	Daria Babushok (US)
<b>11:00 – 11:30</b>	<b>Coffee Break</b>	
<b>11:30 – 12:45</b>	<b>Session VI: Initiative session</b> <b>Chairs:</b> <i>Jakob Passweg (CH) &amp; Andrea Bacigalupo (IT)</i>	
<b>11:30 – 11:55</b>	ICARIIS initiative	Régis P. de la Tour (FR)
<b>11:55 – 12:20</b>	AA treatment decisions/algorithm	Rodrigo Calado (BR)
<b>12:20 – 12:45</b>	Status of art: HCT versus IST (SAAWP initiatives)	Austin Kulasekararaj (UK) Antonio Risitano (IT)
<b>12:45 – 13:30</b>	<b>Lunch Break</b>	
<b>13:30 – 14:15</b>	<b>Industry Symposium kindly sponsored by Novartis:</b> <b>Bone Marrow Failure and Complement Dysregulation: Managing Overlapping AA and PNH</b> <b>Chair:</b> <i>Beatrice Drexler (CH)</i>	
<i>This symposium is organized and funded by Novartis and is intended for an audience of non-US HCPs within the context of the EBMT Severe Aplastic Anaemia Working Party Educational Course 2025 on 9-11 October 2025, in Basel, Switzerland. This presentation may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities.</i>		
<b>13:30 – 13:42</b>	Overview of AA and PNH: From Pathophysiology to Practice	Beatrice Drexler (CH)
<b>13:42 – 14:07</b>	Best Practice in Action: Expert Perspectives on AA and PNH Care <i>Interactive case-based discussion</i>	Shinji Nakao (JP) Morag Griffin (UK)
<b>14:07 – 14:15</b>	Audience Q&A	All
<b>14:15 – 15:30</b>	<b>Session VII: PNH</b> <b>Chairs:</b> <i>Rodrigo Calado (BR) &amp; Austin Kulasekararaj (UK)</i>	
<b>14:15 – 14:35</b>	Therapeutic algorithm in 2025 for PNH	Morag Griffin (UK)
<b>14:35 – 14:55</b>	HSCT in PNH	Camilla Frieri (IT)
<b>14:55 – 15:15</b>	Future directions in PNH	Régis P. de la Tour (FR)
<b>15:15 – 15:30</b>	Discussion	
<b>15:30 – 16:00</b>	<b>Coffee Break</b>	
<b>16:00 – 17:15</b>	<b>Session VIII: The patients, the nurses and caregivers perspective</b> <b>Chairs:</b> <i>Britta Höchsmann (DE) &amp; Jens Panse (DE)</i>	
<b>16:00 – 16:25</b>	Infectious risk in AA patients	Flore S. de Fontbrune (FR)
<b>16:25 – 16:50</b>	Deciphering fatigue in AA/PNH for future care	Pascale Burmester (DE)
<b>16:50 – 17:15</b>	Transition of AA patients	Kelly Hennessy (UK)

**Saturday, 11 October 2025**

**09:00 – 10:10      Session IX: Deciphering acquired versus inherited BMFs in 2025**

**Chairs:** *Maurizio Miano (IT) & Alicia Rovó (CH)*

**09:00 – 09:20**      From the paediatric perspective

**09:20 – 09:40**      From the adults perspective

**09:40 – 10:10**      New germline kids on the block 2025 and monitoring of iBMFs

Carlo Dufour (IT)

Simone Feurstein (DE)

Marcin Wlodarski (DE)

**10:10 – 10:40      Coffee Break**

**10:40 – 11:30      Session X: Long-term outcome**

**Chairs:** *André Tichelli (CH) & Simone Cesaro (IT)*

**10:40 – 10:50**      Cutting edge message from the chair

**10:50 – 11:10**      Long term outcome in IST versus HCT

**11:10 – 11:30**      How to follow up on QoL in AA?

Antonio Risitano (IT)

Beatrice Drexler (CH)

Jens Panse (DE)

**11:30 – 12:30      Session XI: Future Directions**

**Chairs:** *Beatrice Drexler (CH) & Anna Sureda (ES)*

**11:30 – 11:55**      Finding the individual trigger in acquired AA

**11:55 – 12:20**      New kids on the block (Ruxo, Tregs, ...)

**12:20 – 12:30**      Closing remarks

Jaroslawn Maciejewski (US)

Shreyans Gandhi (UK)





# Severe Aplastic Anaemia Working Party Educational Course

Basel, Switzerland  
9-11 October 2025

## WITH THANKS TO OUR SPONSORS

Silver Partner & Industry symposium



Industry symposium

